RecruitingPhase 2NCT06839989

An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC

Studying Human infection by orthopoxvirus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Tropical Medicine, Belgium
Principal Investigator
Laurens Liesenborghs, MD
Institute of Tropical Medicine
Intervention
Mpox vaccination with MVA-BN(biological)
Enrollment
600 enrolled
Eligibility
18-45 years · All sexes
Timeline
20252025

Study locations (1)

Collaborators

MSF Médecins Sans Frontières Belgium · Institut National pour la Recherche Biomedicale (INRB)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06839989 on ClinicalTrials.gov

Other trials for Human infection by orthopoxvirus

Additional recruiting or active studies for the same condition.

See all trials for Human infection by orthopoxvirus

← Back to all trials